Roubaix Capital LLC Invests $1.82 Million in MaxCyte, Inc. (NASDAQ:MXCT)

Roubaix Capital LLC purchased a new position in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 386,201 shares of the company's stock, valued at approximately $1,815,000. Roubaix Capital LLC owned 0.37% of MaxCyte as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Victory Capital Management Inc. grew its stake in shares of MaxCyte by 23.0% during the 4th quarter. Victory Capital Management Inc. now owns 12,316 shares of the company's stock worth $58,000 after acquiring an additional 2,306 shares during the period. M&T Bank Corp grew its stake in shares of MaxCyte by 3.4% during the 3rd quarter. M&T Bank Corp now owns 163,513 shares of the company's stock worth $510,000 after acquiring an additional 5,443 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of MaxCyte by 350.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company's stock worth $56,000 after acquiring an additional 9,323 shares during the period. SG Americas Securities LLC grew its stake in shares of MaxCyte by 28.6% during the 4th quarter. SG Americas Securities LLC now owns 48,550 shares of the company's stock worth $228,000 after acquiring an additional 10,800 shares during the period. Finally, Johnson Investment Counsel Inc. bought a new position in shares of MaxCyte during the 3rd quarter worth $34,000. Institutional investors own 68.81% of the company's stock.

Analyst Ratings Changes

MXCT has been the subject of several research reports. Stephens reiterated an "overweight" rating and set a $11.00 price target on shares of MaxCyte in a research note on Tuesday, April 23rd. BTIG Research cut their target price on MaxCyte from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, March 13th. Finally, William Blair restated an "outperform" rating on shares of MaxCyte in a research note on Wednesday, March 13th.

MaxCyte Stock Performance

NASDAQ MXCT traded up $0.01 during trading hours on Friday, hitting $4.74. The company had a trading volume of 358,721 shares, compared to its average volume of 628,057. MaxCyte, Inc. has a 52 week low of $2.45 and a 52 week high of $5.55. The firm has a 50 day simple moving average of $4.11 and a 200 day simple moving average of $4.40. The firm has a market capitalization of $495.54 million, a price-to-earnings ratio of -13.54 and a beta of 1.36.

MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its quarterly earnings results on Tuesday, March 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.05. MaxCyte had a negative return on equity of 15.68% and a negative net margin of 83.00%. The firm had revenue of $15.67 million during the quarter, compared to the consensus estimate of $15.60 million. On average, research analysts forecast that MaxCyte, Inc. will post -0.51 earnings per share for the current year.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.